Perspectives on Advanced Basal Cell Carcinoma

Each year, physicians diagnose an estimated 2 to 3 million new cases of basal cell carcinoma (BCC) in the United States alone. Identified in its early stage, BCC typically can be cured with complete surgical excision and/or radiation. But, for the the more than 20,000 cases that progress to locally advanced or metastatic BCC annually, diagnosis, treatment, and management can be much more complex.1,2,3,4,5,6

In this exclusive report, experts in dermatology and oncology detail best-practice recommendations for developing an optimal care regimen based on the patient’s individual case. They provide a framework to determine when surgery is a solution, when it is not, and what is new to the armamentarium to address issues of efficacy, safety, and tolerability. This practical resource offers a comprehensive guide for meeting the challenges of advanced BCC—from diagnosis and team building to monitoring and long-term management.


1. Puig S, Berrocal A. Management of high-risk and advanced basaI cell carcinoma. Clin Transl Oncol. 2015;17(7):497-503.
2. Cameron MC, Lee E, Hibler BP, et aI. Basal cell carcinoma: epidemiology; pathophysiology; cIinicaI and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303-317.
3. Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev. 2018;64:1-10.
4. Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal celI carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151(9):976-981.
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Basal Cell Skin Cancer V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 1, 2021. To view the most recent and complete version of the guidelines, go onIine to
6. Skin Cancer Foundation. Our new approach to a challenging skin cancer statistic. Published April 1, 2021. Our New Approach to a Challenging Skin Cancer Statistic

© 2024 MJH Life Sciences

All rights reserved.